Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1924-2015Class II

HDL-Cholesterol gen.3. For the quantitative determination of high-density lipoprotein Cholesterol (HDL-C) in...

Roche Diagnostics GmbH / initiated 2015-05-07 / Terminated

Roche Diagnostics Operations, Inc. began a recall of HDL-Cholesterol gen.3. For the quantitative determination of high-density lipoprotein Cholesterol (HDL-C) in serum and plasma on . FDA classified it as Class II and gives the reason as "Possible drug interference when using the Trinder reaction method on multiple Cobas Analyzers. Results of Trinder tests may be falsely decreased when the tests are run with urine samples (Creatinine plus and Uric Acid...". As of , the recall status on record is Terminated.

Recall record

Recall number
Z-1924-2015
Classification
Class II
Status
Terminated
Initiated
Posted
Terminated
Recalling firm
Roche Diagnostics GmbH
Product
HDL-Cholesterol gen.3. For the quantitative determination of high-density lipoprotein Cholesterol (HDL-C) in serum and plasma.
Product code
LBS Ldl & Vldl Precipitation, Cholesterol Via Esterase-Oxidase, Hdl
Reason for recall
Possible drug interference when using the Trinder reaction method on multiple Cobas Analyzers. Results of Trinder tests may be falsely decreased when the tests are run with urine samples (Creatinine plus and Uric Acid applications only) or blood samples collected before sufficient time has lapsed after the administration of the drugs Acetaminophen and N-acetylcysteine.
FDA root cause
Under Investigation by firm
Action
Roche Diagnostics initiated a voluntary recall and the Urgent Medical Device Correction notices were sent via UPS Ground on 05/07/2015 to customers. Customers were notified of the interference and the method sheets and package inserts will be updated with the new interference claims. The firm plans to monitor any non-responding accounts and address those customers with follow-up attempts to distribute recall notices. The firm plans to conduct level B effectiveness checks via fax and phone. Until the new method sheets are available, the Urgent Medical Device Correction serves as the updated labeling. Roche is not requesting return of the affected product. Customers may contact Todd Siesky Corporate Communications Director, Phone: 317.521.3911, Fax: 317.521.4696, E-mail: [email protected]. For technical questions, contact the Customer Support Center at 1-800-428-2336
Quantity in commerce
6255 analytical units
Distribution
US (nationwide) including PR.
Product codes and lots
Catalog Numbers: 05401470190; 03263991190; 05168589190; 03263991190.

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1924-2015
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1920-2015Class IITerminatedVoluntary: Firm initiated
Z-1921-2015Class IITerminatedVoluntary: Firm initiated
Z-1922-2015Class IITerminatedVoluntary: Firm initiated
Z-1923-2015Class IITerminatedVoluntary: Firm initiated
Z-1924-2015Class IITerminatedVoluntary: Firm initiated
Z-1925-2015Class IITerminatedVoluntary: Firm initiated
Z-1926-2015Class IITerminatedVoluntary: Firm initiated
Z-1927-2015Class IITerminatedVoluntary: Firm initiated
Z-1928-2015Class IITerminatedVoluntary: Firm initiated
Z-1929-2015Class IITerminatedVoluntary: Firm initiated
Z-1930-2015Class IITerminatedVoluntary: Firm initiated
Z-1931-2015Class IITerminatedVoluntary: Firm initiated